Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

18.90
-0.0200-0.11%
Post-market: 18.900.00000.00%19:30 EDT
Volume:653.64K
Turnover:12.43M
Market Cap:871.75M
PE:85.91
High:19.32
Open:19.06
Low:18.80
Close:18.92
52wk High:60.86
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:0.86
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2200
EPS(LYR):1.80
ROE:5.10%
ROA:-0.48%
PB:3.58
PE(LYR):10.50

Loading ...

Oddity Tech Q1 EPS USD -0.38

THOMSON REUTERS
·
Jun 02

Oddity Tech Q1 Adjusted Ebitda USD -7 Million

THOMSON REUTERS
·
Jun 02

Oddity Tech - Expects Positive Adj Ebitda for Full Year 2026

THOMSON REUTERS
·
Jun 02

Oddity Tech Reports First Quarter 2026 Results, Makes Progress Toward Normalization

THOMSON REUTERS
·
Jun 02

U.S. Earnings Preview: Before Market Open June 2

Dow Jones
·
Jun 02

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jun 01

Oddity Tech Ltd expected to post earnings of 1 cent a share - Earnings Preview

Reuters
·
May 29

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 28

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

GlobeNewswire
·
May 23

KeyBanc card data shows ‘significant improvement’ for Oddity

TIPRANKS
·
May 22

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

GlobeNewswire
·
May 21

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

GlobeNewswire
·
May 21

Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

prnewswire
·
May 18

Press Release: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Dow Jones
·
May 16

Oddity Tech schedules first-quarter results release, earnings call

Reuters
·
May 15

ODDITY to Announce First Quarter 2026 Financial Results on June 2, 2026

GlobeNewswire
·
May 15

Press Release: Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

Dow Jones
·
May 14

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

GlobeNewswire
·
May 14

U.S. Earnings Preview: After Market Close May 12

Dow Jones
·
May 13